Shots:

• The two companies collaborated to facilitate the development of digital health tools for the earlier screening of cardiovascular diseases- including HF
• AstraZeneca and Eko will accelerate the development of Eko algorithms- enhancing clinical trials with Eko technology- and potentially building new HF detection solutions. The agreement allows the companies to harness the potential to improve access to individualized care and generate better patient outcomes
• In Dec’2019- Eko has received the US FDA’s BT designation for a novel ECG-based algorithm that can identify reduced LVEF. If approved- the algorithm will be compatible with the DUO- Eko’s handheld stethoscope- and ECG device

­ Ref: PRNewswire | Image: Physician Practice